Pathophysiology guided treatment of nonalcoholic steatohepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue SUPPL.2, 2012, Pages 58-64

  Nguyen, Tuyet A T ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Insulin resistance; Nonalcoholic fatty liver; Nonalcoholic steatohepatitis; Vitamin E

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 ETHYL CHEDEOXYCHOLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETAINE; CANNABINOID 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; EXENDIN 4; EZETIMIBE; FARNESOID X RECEPTOR AGONIST; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INCRETIN; LINOLEIC ACID; LIRAGLUTIDE; LIVER PROTECTIVE AGENT; METFORMIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PHOSPHOLIPID DERIVATIVE; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SILYMARIN; TELMISARTAN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VALSARTAN;

APOPTOSIS; BILIARY CIRRHOSIS; BRAIN HEMORRHAGE; CANCER RISK; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENDOPLASMIC RETICULUM STRESS; EVIDENCE BASED MEDICINE; EXERCISE; FATTY LIVER; FRACTURE; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID DIET; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; METABOLIC SYNDROME X; NAUSEA; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84856957313     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07018.x     Document Type: Review

References (49)

1. Browning JD, Szczepaniak LS, Dobbins R etal. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
2. Gruen ML, Hao M, Piston DW, Hasty AH. Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. Am. J. Physiol. Cell Physiol. 2007; 293: C1481-8.
3. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br. J. Nutr. 2008; 100: 227-35.
4. Perez-Carreras M, Del Hoyo P, Martin MA etal. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1007.
5. Sanyal AJ, Campbell-Sargent C, Mirshahi F etal. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
6. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 290: G852-8.
7. Puri P, Baillie RA, Wiest MM etal. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-90.
8. Puri P, Mirshahi F, Cheung O etal. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 568-76.
9. Syn WK, Jung Y, Omenetti A etal. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009; 137: 1478-88 e8.
10. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 2007; 86: 285-300.
11. Promrat K, Kleiner DE, Niemeier HM etal. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
12. Cotler SJ, Vitello JM, Guzman G, Testa G, Benedetti E, Layden TJ. Hepatic decompensation after gastric bypass surgery for severe obesity. Dig. Dis. Sci. 2004; 49: 1563-8.
13. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst. Rev. 2010; (1): CD007340.
14. Uygun A, Kadayifci A, Isik AT etal. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2004; 19: 537-44.
15. Bugianesi E, Gentilcore E, Manini R etal. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2005; 100: 1082-90.
16. Lavine JE, Schwimmer JB, Van Natta ML etal. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-68.
17. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2010; 32: 1211-21.
18. Sanyal AJ, Chalasani N, Kowdley KV etal. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010; 362: 1675-85.
19. Klonoff DC, Buse JB, Nielsen LL etal. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24: 275-86.
20. Samson SL, Sathyanarayana P, Jogi M etal. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54: 3093-100.
21. Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Adv. Ther. 2008; 25: 1141-74.
22. Enjoji M, Kotoh K, Kato M etal. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. Int. J. Mol. Med. 2008; 22: 521-7.
23. Yokohama S, Yoneda M, Haneda M etal. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5.
24. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 2009; 15: 942-54.
25. Arendt BM, Allard JP. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required? Am. J. Gastroenterol. 2011; 106: 78-80.
26. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2003; 98: 2485-90.
27. Sanyal AJ, Mofrad PS, Contos MJ etal. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2004; 2: 1107-15.
28. Dufour JF, Oneta CM, Gonvers JJ etal. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2006; 4: 1537-43.
29. Chalasani NP, Sanyal AJ, Kowdley KV etal. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp. Clin. Trials 2009; 30: 88-96.
30. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005; 142: 37-46.
31. Sesso HD, Buring JE, Christen WG etal. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008; 300: 2123-33.
32. Klein EA, Thompson IM Jr, Tangen CM etal. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
33. Abdelmalek MF, Sanderson SO, Angulo P etal. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50: 1818-26.
34. Loguercio C, Federico A, Trappoliere M etal. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig. Dis. Sci. 2007; 52: 2387-95.
35. Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 2007; (1): CD005160.
36. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev. Med. Chem. 2011; 11: 753-62.
37. Van Wagner LB, Koppe SW, Brunt EM etal. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann. Hepatol. 2011; 10: 277-86.
38. Zein CO, Yerian LM, Gogate P etal. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-9.
39. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004; 99: 2365-8.
40. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2007; 22: 634-8.
41. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2008; 42: 413-18.
42. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol. 1999; 31: 384.
43. Yoneda M, Fujita K, Nozaki Y etal. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol. Res. 2010; 40: 613-21.
44. Hyogo H, Ikegami T, Tokushige K etal. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol. Res. 2011; 41: 1057-65.
45. Hyogo H, Tazuma S, Arihiro K etal. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-18.
46. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol. 2007; 47: 135-41.
47. Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br. J. Pharmacol. 2011; 163: 1432-40.
48. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur. Heart J. 2008; 29: 1761-71.
49. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005; 353: 2121-34.